EDMONTON, July 27 /CNW/ - Biomira Inc. (Nasdaq Global Market: BIOM)
(TSX:BRA), a leading developer of innovative therapeutic approaches to cancer
management, today reported financial results for the three and six months
ended June 30, 2006.
"This has been a solid quarter for Biomira, with our lead product
Stimuvax(R) continuing to make important progress toward the start of a phase
3 trial," said Edward Taylor, Biomira's interim President and CEO. "With
Merck's greater involvement, we have turned our attention to bolstering the
pipeline of products between Stimuvax(R) and BGLP40 Liposomal Vaccine
(L-BGLP40) and we have already seen a number of promising opportunities, which
would benefit from Biomira's expertise in moving products through all stages
of development. We have also made cost containment a priority as we seek to
maximize and reallocate our resources in the most appropriate fashion. We look
forward to further significant product news in the second half of the year."
<<
Second Quarter Highlights
- Lead cancer vaccine Stimuvax(R) is on track to enroll the first
patient in a large, multi-national phase 3 trial in non-small cell
lung cancer (NSCLC) by the end of the year. Biomira is finalizing the
amendments to the existing supply and collaboration agreements with
Merck KGaA of Darmstadt, Germany (Merck) for the future clinical
development of Stimuvax(R). Merck and Biomira are in the process of
preparing the protocol to commence a large scale trial that will
likely involve approximately 1300 men and women with Stage III cancer
in approximately 30 countries and 250 clinical trial sites.
- In May, the Company announced that Dr. Alex McPherson would step down
as President and CEO after a 15 year tenure. His position has been
taken on an interim basis by Edward Taylor, the Company's Chief
Financial Officer and Vice President, Finance and Administration. Dr.
McPherson subsequently stepped down from the Board of Directors after
19 years of service. Mr. Taylor was also appointed to the Board of
Directors. The Company is in the process of seeking a new President
and CEO and potentially looking for new Board members with skills
that would complement the current Board. While this can be a lengthy
process, the Company has developed a strategic direction for moving
forward, with the support of the Board of Directors.
- In June, Biomira announced that it had retained Janney Montgomery
Scott LLC (Janney) to help the Company explore pipeline development
options. Janney is working with Biomira to identify in-licensing and
acquisition opportunities that are a natural fit with the Company's
core competencies and resources in the development of innovative,
targeted therapeutics that extend the quality and duration of
patients' lives. Biomira is seeking mid-stage products with good
safety and efficacy data, and potentially option or licensing rights
to earlier stage product candidates. The immediate focus is on
oncology products.
- The Journal of Urology recently published study results showing that
Stimuvax(R) could slow rising Prostate Specific Antigen (PSA) levels
in some post-surgical prostate cancer patients, potentially delaying
the need for initiation of androgen deprivation therapy (ADT). The
study results were described in an article entitled "A Pilot Study of
the Liposomal MUC1 vaccine BLP25 in Prostate Specific Antigen
Failures After Radical Prostatectomy." PSA is a tumour marker used by
physicians to detect prostate cancer, monitor treatment effects and
guide medical management of men with this disease, rising levels
being predictive of relapse and disease progression. The acceptance
and publication of these clinical trial results in a leading medical
journal support the potential value of cancer vaccine approaches to
patients with few therapeutic options and our future plans for this
product candidate, which include the upcoming phase 3 study in NSCLC.
- Biomira's Synthetic Biologics Business Unit (SBBU) is in discussions
with several companies, which are now performing due diligence on the
synthetic adjuvants and compounds developed by the SBBU. The Company
hopes to begin finalizing agreements in the coming year.
- In May, Prima BioMed announced favourable results from its phase 2a
study in ovarian cancer. Our agreement with Prima BioMed provides
that we have the sole option to elect to either license the exclusive
worldwide commercialization rights (excluding Asia, Australia and New
Zealand), or only the North American region, for this product
candidate, following conclusion of the phase 2a trial in ovarian
cancer, or an option to simply maintain the current license that
grants certain rights to Biomira technology to Prima BioMed. We will
make that election following our review of the phase 2a clinical
trial data later this year.
- Pre-clinical work continues on the Company's third-generation product
candidate, L-BGLP40. We believe the pre-clinical work will warrant
moving into clinical trials in 2007 and we hope to find a partner to
take over the clinical development in the coming year.
>>
Financial Update
Financial results for the six months ended June 30, 2006 reflect a
consolidated net loss from operations of $9.8 million or $0.11 per share
compared to $9.2 million or $0.12 per share for the same period in 2005. The
increased net loss of $0.6 million in 2006 arises from lower revenues of
$0.4 million, reduced investment and other income of $0.4 million and higher
general and administrative expenses of $1.0 million, partially offset by
decreased research and development expenditures of $0.9 million and marketing
and business development expenses of $0.3 million. The increased net loss
primarily relates to workforce reduction and exiting costs incurred in the
first half of 2006, partially offset by a deferral of Stimuvax(R)
manufacturing costs incurred in preparation for the planned Merck-led phase 3
trial in NSCLC expected to commence by the end of the year, and reduced
clinical expenditures in anticipation of finalizing the amendments to the
existing supply and collaboration agreements with Merck for the future
clinical development of Stimuvax(R).
As at June 30, 2006, our cash and cash equivalents and short-term
investments were $28.7 million compared to $21.4 million at the end of 2005,
an increase of $7.3 million or 34%.
For a further discussion of the Company's financial results for the six
months ended June 30, 2006, please refer to the Company's unaudited
consolidated financial statements and the Company's Management Discussion &
Analysis of Financial Condition and Results of Operations included in this
report.
Biomira Inc.
Biomira is a biotechnology company specializing in the development of
innovative therapeutic approaches to cancer management. Biomira's commitment
to the treatment of cancer currently focuses on the development of synthetic
vaccines and novel strategies for cancer immunotherapy. We are The Cancer
Vaccine People(TM).
Management's Discussion and Analysis of Financial Condition and Results
of Operations
Management's Discussion and Analysis of Financial Condition and Results
of Operations (MD&A), prepared as at July 14, 2006, should be read in
conjunction with the unaudited consolidated financial statements and
accompanying notes for the six months ended June 30, 2006, included hereafter,
as well as the audited consolidated financial statements and MD&A for the
fiscal year ended December 31, 2005. Except as discussed below, all other
factors referred to and discussed in the MD&A for fiscal year 2005 remain
substantially unchanged.
Overview of the Business
Biomira Inc. is an international biotechnology company headquartered in
Canada operating primarily in a single business segment, the research and
development of innovative therapeutic approaches to cancer management. Our
research and development efforts are currently focused on our core competency
in immunotherapeutics, particularly developing synthetic vaccines and novel
strategies for cancer immunotherapy. Our strategic mission is to build a
sustainable and profitable company by bringing patients innovative, targeted
therapeutics that extend quality and duration of life.
Stimuvax(R)
Corporate resources in the first six months of 2006 were primarily
directed towards the ongoing transition of most of the administrative and
financial responsibility for the development and commercialization of
Stimuvax(R) to Merck KGaA of Darmstadt, Germany (Merck). Our lead cancer
vaccine is on track to enroll the first patient in a large, multi-national
phase 3 trial in non-small cell lung cancer (NSCLC) by the end of the year.
Merck and Biomira are currently in the process of preparing the protocol to
commence a large scale trial that will likely involve approximately 1300 men
and women with Stage III cancer in approximately 30 countries and 250 clinical
trial sites. At the same time, we continue to work towards finalizing the
amendments to the existing supply and collaboration agreements with Merck for
the future clinical development of Stimuvax(R).
The Journal of Urology recently published study results showing that
Stimuvax(R) could slow rising Prostate Specific Antigen (PSA) levels in some
post-surgical prostate cancer patients, potentially delaying the need for
initiation of androgen deprivation therapy (ADT). The study results were
described in an article entitled "A Pilot Study of the Liposomal MUC1 vaccine
BLP25 in Prostate Specific Antigen Failures After Radical Prostatectomy." PSA
is a tumour marker used by physicians to detect prostate cancer, monitor
treatment effects and guide medical management of men with this disease,
rising levels being predictive of relapse and disease progression. The
acceptance and publication of these clinical trial results in a leading
medical journal support the potential value of cancer vaccine approaches to
patients with few therapeutic options and our future plans for this product
candidate, which include the upcoming phase 3 study in NSCLC.
Business Development
Our Synthetic Biologics Business Unit continues to focus on exploring the
full potential of chemically synthesized biologicals for use in protective and
therapeutic vaccines. We continue to actively seek licensing opportunities for
our synthetic adjuvants and are currently in discussions with several
companies, which are now performing due diligence on our synthetic adjuvants
and compounds. We hope to begin finalizing agreements in the coming year.
Pre-clinical work continues on our third-generation product candidate,
BGLP40 Liposomal Vaccine (L-BGLP40), a completely synthetic MUC1 based
liposomal, multiple target cancer vaccine, which we believe may provide
benefit in several cancer indications. L-BGLP40 is a vaccine designed to evoke
both a cellular and humoral immune response against major cancer-associated
target epitopes expressed on adenocarcinomas. We believe the pre-clinical work
will warrant moving into clinical trials in 2007 and we hope to find a partner
to take over the clinical development in the coming year.
In May, Prima BioMed announced favourable results from its phase 2a study
in ovarian cancer. Our agreement with Prima BioMed provides that we have the
sole option to elect to either license the exclusive worldwide
commercialization rights (excluding Asia, Australia and New Zealand), or only
the North American region, for this product candidate, following conclusion of
the phase 2a trial in ovarian cancer, or an option to simply maintain the
current license that grants certain rights to Biomira technology to Prima
BioMed. We will make that election following our review of the phase 2a
clinical trial data later this year.
Corporate Update
In the first quarter of 2006 we began a limited restructuring process for
the Company to ensure that we have the right people and expertise to carry out
the business of the Company, while we transition most of the administrative
and financial responsibility for the development and commercialization of
Stimuvax(R) to Merck. This limited restructuring process has continued through
the second quarter and to date we have incurred workforce reduction costs of
$1.4 million, as disclosed in Note 6, Workforce Reduction Costs, of our
unaudited consolidated financial statements for the six months ended June 30,
2006, included hereafter. During this process we continue to maintain our core
expertise in all necessary areas to take advantage of opportunities presented
to us. However, we do expect further workforce reductions once the Merck
transition has been completed and once we more fully understand what expertise
is needed for potential new product candidates that we hope to in-license.
In May, we announced that Dr. Alex McPherson would step down as President
and CEO after a 15 year tenure. His position has been taken on an interim
basis by Edward Taylor, the Company's Chief Financial Officer and Vice
President, Finance and Administration. Dr. McPherson subsequently stepped down
from the Board of Directors after 19 years of service. Mr. Taylor was also
appointed to the Board of Directors. The Company is in the process of seeking
a new President and CEO and potentially looking for new Board members with
skills that would complement the current Board. While this can be a lengthy
process, the Company has developed a strategic direction for moving forward,
with the support of the Board of Directors.
In June, we announced that the Company had retained Janney Montgomery
Scott LLC (Janney) to help explore pipeline development options. Janney is
working with Biomira to identify in-licensing and acquisition opportunities
that are a natural fit with the Company's core competencies and resources in
the development of innovative, targeted therapeutics that extend the quality
and duration of patients' lives. We are seeking mid-stage products with good
safety and efficacy data, and potentially option or licensing rights to
earlier stage product candidates. The immediate focus is on oncology products.
With the development program of Stimuvax(R) in the hands of Merck
effective March 1, 2006, we have begun to further develop our follow-on
vaccine, L-BGLP40, and to assess potential in-licensing opportunities. We have
also made cost containment a priority as we seek to maximize and reallocate
our resources in the most appropriate fashion, and move forward with a focus
on building additional shareholder value through the development of a pipeline
for the future of the Company.
Non-GAAP Measures
We refer to terms that are not specifically defined in the CICA Handbook
and do not have any standardized meaning prescribed by generally accepted
accounting principles (GAAP). These non-GAAP measures may not be comparable to
similar measures presented by other companies. Biomira refers to and uses the
term "working capital" in this MD&A, which is defined as current assets less
current liabilities.
Results of Operations
Financial results for the six months ended June 30, 2006 reflect a
consolidated net loss from operations of $9.8 million or $0.11 per share
compared to $9.2 million or $0.12 per share for the same period in 2005. The
increased net loss of $0.6 million in 2006 arises from lower revenues of
$0.4 million, reduced investment and other income of $0.4 million and higher
general and administrative expenses of $1.0 million, partially offset by
decreased research and development expenditures of $0.9 million and marketing
and business development expenses of $0.3 million. The increased net loss
primarily relates to workforce reduction and exiting costs incurred in the
first half of 2006, partially offset by a deferral of Stimuvax(R)
manufacturing costs incurred in preparation for the planned Merck-led phase 3
trial in NSCLC expected to commence by the end of the year, and reduced
clinical expenditures in anticipation of finalizing the amendments to the
existing supply and collaboration agreements with Merck for the future
clinical development of Stimuvax(R).
Revenues
Contract research and development revenue for the six months ended
June 30, 2006, totalling $1.3 million compared to $1.6 million for the same
period in 2005, represents contract research and development funding received
from Merck associated with Stimuvax(R). The decrease in revenues is primarily
attributable to reduced clinical expenditures in anticipation of finalizing
the amendments to the existing supply and collaboration agreements with Merck
for the future clinical development of Stimuvax(R).
Licensing revenues from collaborative arrangements for the six months
ended June 30, 2006, totalling $0.1 million compared to $0.1 million for the
same period in 2005, represents the amortization of upfront payments received
from Merck and an upfront sub-licensing fee from CancerVac Pty. Ltd. upon
commencement of the respective collaborations.
Licensing, royalties and other revenue for the six months ended June 30,
2006, totalling $0.1 million compared to $0.2 million for the same period in
2005, primarily consists of contract manufacturing activities utilizing
various Biomira patented technologies and compounds for external customers.
Operating Expenses
Research and Development
Research and development expenditures for the six months ended June 30,
2006 totalled $6.9 million compared to $7.8 million for the same period in
2005. The decrease of $0.9 million is primarily attributable to a deferral of
Stimuvax(R) manufacturing costs incurred in preparation for the planned
Merck-led phase 3 trial in NSCLC expected to commence by the end of the year,
and reduced clinical expenditures in anticipation of finalizing the amendments
to the existing supply and collaboration agreements with Merck for the future
clinical development of Stimuvax(R). These expense reductions have been
partially offset by workforce reduction costs as disclosed in Note 6,
Workforce Reduction Costs, of our unaudited consolidated financial statements
for the six months ended June 30, 2006, included hereafter.
General and Administrative
General and administrative expenses for the six months ended June 30,
2006 totalled $4.3 million compared to $3.3 million for the same period in
2005. The increase of $1.0 million is primarily attributable to accrued
non-contractual and contractual employee exiting costs currently under
negotiation of $0.6 million and $0.3 million respectively, and workforce
reduction costs as disclosed in Note 6, Workforce Reduction Costs, of our
unaudited consolidated financial statements for the six months ended June 30,
2006, included hereafter.
Marketing and Business Development
Marketing and business development expenditures for the six months ended
June 30, 2006 totalled $0.4 million compared to $0.7 million for the same
period in 2005. Marketing and business development expenditures include
corporate administrative expenses associated with these functions, as well as
costs associated with licensing activities related to pre-clinical and early
stage technologies. The decrease of $0.3 million is primarily due to reduced
marketing activities as we continue to focus our efforts on assessing
potential in-licensing opportunities.
Amortization
Amortization expense for the six months ended June 30, 2006, totalling
$0.2 million, was similar to the same period in 2005. Amortization expense
relates to facility leaseholds and equipment, certain licensing rights, and
other assets.
Investment and Other Income
Investment and other income for the six months ended June 30, 2006,
totalling $0.4 million, compared to $0.8 million for the same period in 2005,
comprises income from cash and investments and foreign exchange gains and
losses. The decrease of $0.4 million is primarily attributable to the impact
of foreign exchange fluctuations on our U.S. dollar holdings, which has
resulted in a foreign exchange loss of $0.1 million for the six months ended
June 30, 2006 compared to a foreign exchange gain of $0.4 million for the same
period in 2005.
Liquidity and Capital Resources
Liquidity
As at June 30, 2006, our cash and cash equivalents and short-term
investments ("cash reserves") were $28.7 million compared to $21.4 million at
the end of 2005, an increase of $7.3 million or 34%. Major contributors to the
net change included $17.5 million in net financing proceeds offset by
$10.0 million used in operations, which includes workforce reduction costs of
$0.9 million. With the development program for Stimuvax(R) in the hands of
Merck effective March 1, 2006, coupled with the additional net financing
proceeds which we were able to secure in January 2006, we believe that
sufficient cash reserves are in place to operate well into the latter half of
2007 and potentially into early 2008.
Working capital increased by $8.6 million from the end of 2005, to
$28.5 million from $19.9 million and is attributable to a $7.3 million
increase in cash reserves and a $1.7 million increase in prepaid expenses and
other, offset by a decrease of $0.4 million in accounts receivable. The
increase in prepaid expenses and other primarily relates to deferred
Stimuvax(R) manufacturing costs that have been incurred in preparation for the
planned Merck-led phase 3 trial in NSCLC expected to commence by the end of
the year. The decrease in accounts receivable primarily relates to reduced
contract research and development funding as we continue the process of
transitioning most of the administrative and financial responsibilities for
the development of Stimuvax(R) over to Merck.
Financing
In January 2006, we were able to raise U.S. $16.07 million (CDN.
$18.4 million), before issue costs, by issuing 10,572,368 units, each unit
consisting of one common share and 0.25 of a warrant, at an issue price of
U.S. $1.52. Each warrant entitles the holder thereof to purchase one common
share of the Company at an exercise price of U.S. $2.50. The warrants have a
42 month term and a no-exercise period of six months.
Capital Resources
Anticipating future funding requirements to further our product pipeline
and in-licensing activities, we registered a U.S. $100 million Base Shelf
Prospectus with the applicable regulatory authorities in Canada and the U.S.
in July 2004. This financing mechanism will be expiring in the third quarter
of 2006, and our current expectation is that we will register a new Base Shelf
Prospectus to ensure that a financing mechanism remains in place to allow us
to take advantage of future favorable financing opportunities in a timely
manner. In addition, there are 3.8 million warrants outstanding, at a
weighted-average exercise price of U.S. $2.77. Based on our NASDAQ closing
share price of U.S. $1.07 on June 30, 2006, the warrants outstanding are
currently not in the money.
Additional capital resources may be required depending on the outcomes
associated with activities related to the in-licensing of new product
candidates, and activities associated with the further development of other
products in our pipeline including L-BGLP40. Assuming continued investor
support for our equity offerings, and the successful registration of a planned
new Base Shelf Prospectus in the third or fourth quarter of 2006, such
additional capital resources could be derived from this form of financing
mechanism, or receipt of milestone payments anticipated from Merck later this
year under the terms of the letter of intent disclosed in Note 5,
Collaborative Agreements, of our unaudited consolidated financial statements
for the six months ended June 30, 2006, included hereafter.
Contractual Obligations and Contingencies
In our continuing operations, we have entered into long-term contractual
arrangements from time to time for our facilities, debt financing, the
provision of goods and services, and acquisition of technology access rights,
among others. The contractual obligations arising from these arrangements,
currently in force over the next ten years, are disclosed in the MD&A section
of our 2005 Annual Report. During the six months ended June 30, 2006, we did
not enter into any new material long-term contractual obligations that are
outside the ordinary course of business.
Off-Balance Sheet Arrangements
As at June 30, 2006, we have not entered into any off-balance sheet
arrangements, except as disclosed in Note 15 Contingencies, Commitments, and
Guarantees in the notes to our audited 2005 consolidated financial statements.
Transactions with Related Parties
During the six months ended June 30, 2006, we did not enter into any
material transactions with related parties.
Outlook
Until one of our products receives regulatory approval and is
successfully commercialized, we anticipate losses for at least the foreseeable
future as our lead product candidate undergoes the final stages of clinical
development. The magnitude of these operating losses will be largely affected
by the timing and scope of future clinical trials and pre-launch activities
related to our products, as well as any new initiatives. Finally, the duration
of the pre-operating losses will depend on the scientific results of such
clinical trials.
We expect that clinical development expenses will decline considerably in
the second half of 2006 with the development program for Stimuvax(R) in the
hands of Merck effective March 1, 2006. Coupling this with the U.S.
$16.07 million (CDN. $18.4 million), before issue costs, in financing we were
able to secure in January 2006 and the expected cash inflows from
collaborative funding arrangements, investment income, and technology
licensing efforts, we believe that our cash and short-term investments in
place will be sufficient to meet operating and capital requirements into the
latter half of 2007 and potentially into early 2008.
We believe that we have in place several key value drivers that may
increase shareholder value in the future. These include: a strong relationship
with Merck; the planned advancement by Merck of Stimuvax(R) into a pivotal
phase 3 registration trial; the possible advancement of clinical programs
related to early stage technologies; and out-licensing opportunities for early
stage product technologies. The key value drivers described above could be
negatively impacted by many factors including: a decision by Merck not to move
forward with or abandon the planned Stimuvax(R) phase 3 registration trial;
Merck's inability to successfully complete the planned Stimuvax(R) phase 3
registration trial; unfavorable results from the planned Stimuvax(R) phase 3
registration trial; ultimate denial or delay of regulatory approval; the
inability to find collaborators or funding for our early stage technologies;
and, a lack of interest in licensing our early stage technologies.
Risks and Uncertainties
The immediate risks and uncertainties facing Biomira may include, but are
not limited to: changing market and industry conditions; clinical trial
results; the establishment of new and continuation of existing corporate
alliances; the impact of competitive products and their pricing; timely
development of existing and new products; the difficulty of predicting
regulatory approval and market acceptance for our products; our ability to
secure and manufacture vaccine supplies for future clinical trials and
commercialization activities on a consistent and economical basis;
availability of capital or other funding; the ability to patent and defend our
intellectual property; the ability to retain and recruit qualified personnel;
and other risks, known or unknown.
Our ability to continue to generate cash to fund the advancement of
clinical programs related to early stage technologies and out-licensing
opportunities for early stage product technologies will depend on several
factors. Among others, these include regulatory support for the planned phase
3 pivotal Stimuvax(R) registration trial; the availability of new financing
through private and/or public offerings on acceptable terms; the timely
advancement of clinical studies; the costs in obtaining regulatory approvals
for our products, if such can be obtained; and the value and timing of
securing licensing and collaborative arrangements in building our pipeline.
Other business risks and uncertainties have not changed significantly
from those disclosed in the MD&A in our 2005 annual report and in other
regulatory filings.
Critical Accounting Policies and Estimates
All of our accounting policies are in accordance with Canadian GAAP
including some which require management to make assumptions and estimates that
could significantly affect the results of operations and financial position.
The significant accounting policies that we believe are the most critical in
fully understanding and evaluating the reported financial results are
disclosed in the MD&A section of our 2005 Annual Report. As well, our
significant accounting policies are disclosed in Note 2, Significant
Accounting Policies, of the notes to our audited consolidated financial
statements for the fiscal year ended December 31, 2005.
Changes in Accounting Policies
Non-Monetary Transactions
Effective January 1, 2006, we adopted the recommendations of CICA
Handbook Section 3831, Non-Monetary Transactions, replacing Section 3830 of
the same title. The new accounting standard requires all non-monetary
transactions be measured at fair value unless certain conditions are
satisfied. The new requirements are effective for non-monetary transactions
initiated in periods beginning on or after January 1, 2006.
We have determined that adoption of Section 3831 does not have an effect
on our financial position or results of operations in the current period
presented.
Implicit Variable Interests under AcG-15
Effective January 1, 2006, we adopted the recommendations of Abstract No.
157, Implicit Variable Interests under AcG-15 (EIC-157). The new abstract
addresses whether a company has an implicit variable interest in a variable
interest entity (VIE) or potential VIE when specific conditions exist. An
implicit variable interest acts the same as an explicit variable interest
except it involves the absorbing and/or receiving of variability indirectly
from the entity (rather than directly). The identification of an implicit
variable interest is a matter of judgment that depends on the relevant facts
and circumstances.
We have determined that adoption of EIC-157 does not have an effect on
our financial position, results of operations or cash flows in the current
period presented.
Supplemental Information
Summary of Quarterly Results
The following is selected quarterly consolidated financial information
from our unaudited quarterly financial statements for each of the eight most
recently completed quarters ending June 30, 2006. Certain of the comparative
figures have been reclassified to conform to the current period's
presentation.
<<
-------------------------------------------------------------------------
For the three month period ended
-------------------------------------------------------------------------
(expressed in 000's except June 30, Mar. 31, Dec. 31, Sept. 30,
per share data) 2006 2006 2005 2005
-------------------------------------------------------------------------
Total Revenue $ 1,156 $ 380 $ 1,115 $ 1,338
-------------------------------------------------------------------------
Research and development cost $ 2,972 $ 3,956 $ 4,455 $ 4,625
-------------------------------------------------------------------------
Net loss $ (4,009) $ (5,800) $ (4,388) $ (5,476)
-------------------------------------------------------------------------
Basic and diluted loss per share $ (0.04) $ (0.07) $ (0.05) $ (0.07)
-------------------------------------------------------------------------
Common shares outstanding 89,389 89,389 78,817 78,817
-------------------------------------------------------------------------
Weighted average number of
common shares outstanding 89,389 85,865 78,660 78,607
-------------------------------------------------------------------------
-------------------------------------------------------------------------
For the three month period ended
-------------------------------------------------------------------------
(expressed in 000's except June 30, Mar. 31, Dec. 31, Sept. 30,
per share data) 2005 2005 2004 2004
-------------------------------------------------------------------------
Total Revenue $ 1,120 $ 804 $ 974 $ 531
-------------------------------------------------------------------------
Research and development cost $ 4,320 $ 3,507 $ 3,198 $ 3,229
-------------------------------------------------------------------------
Net loss $ (4,803) $ (4,358) $ (3,581) $ (4,804)
-------------------------------------------------------------------------
Basic and diluted loss per share $ (0.06) $ (0.06) $ (0.05) $ (0.06)
-------------------------------------------------------------------------
Common shares outstanding 78,817 78,360 78,340 72,562
-------------------------------------------------------------------------
Weighted average number of
common shares outstanding 78,500 78,352 72,941 72,560
-------------------------------------------------------------------------
Outstanding Share Data
As at July 14, 2006, the following classes of shares and equity securities
potentially convertible into common shares were outstanding:
-------------------------------------------------------------------------
Class A preference shares (non-voting) 12,500
Class B preference shares (non-voting) nil
Common shares 89,388,932
Convertible equity securities:
Stock options 4,055,647
Restricted share units 114,000
Warrants 3,825,937
-------------------------------------------------------------------------
>>
Upon exercise or conversion, the stock options, restricted share units
and warrants are convertible into an equal number of common voting shares. Had
the outstanding stock options, restricted share units and warrants been fully
exercised or converted, the aggregate number of common shares outstanding
would be 97,384,516 as at July 14, 2006.
For details relating to the stock options, restricted share units and
warrants, please refer to Notes 10 and 11 of the notes to the audited
consolidated financial statements for the fiscal year ended December 31, 2005
and Note 3 of the unaudited interim consolidated financial statements for the
six months ended June 30, 2006.
Forward-Looking Statements
In order to provide our investors with an understanding of our current
results and future prospects, this report contains statements that are forward
looking. These forward looking statements represent Biomira's intentions,
plans, expectations and beliefs and are based on our experience and our
assessment of historical and future trends and the application of key
assumptions relating to future events and circumstances.
Forward looking statements involve risks and uncertainties related to our
business and the general economic environment, many beyond our control. These
risks, uncertainties and other factors could cause our actual results to
differ materially from those projected in forward-looking statements,
including those predicting the timing or availability of clinical trial
analyses; efficacy, safety and clinical benefit of products; ability to
secure, and timing of, regulatory clearances; timing of product launches in
different markets; ability to retain or secure collaborative partners; ability
to secure and manufacture vaccine supplies; adequacy of financing and reserves
on hand; scope and adequacy of insurance coverage; retention and performance
of contractual third parties, including key personnel; the achievement of
contract milestones; currency exchange rate fluctuations; changes in general
accounting policies; and general economic factors. Although we believe that
the forward-looking statements contained herein are reasonable, we can give no
assurance that our expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement. For a
detailed description of our risks and uncertainties, you are encouraged to
review the official corporate documents filed with the securities regulators
in Canada and the United States.
Additional Information
Additional information relating to Biomira, including a copy of our
Annual Information Form and Proxy Circular, can be found on SEDAR at
www.sedar.com or U.S. EDGAR at www.sec.gov.
<<
Biomira Inc.
Consolidated Balance Sheets
(expressed in thousands of Canadian dollars, except share amounts)
(unaudited)
June 30 December 31
2006 2005(x)
-------------------------------------------------------------------------
ASSETS
CURRENT
Cash and cash equivalents $ 11,463 $ 9,264
Short-term investments 17,274 12,151
Accounts receivable 870 1,279
Prepaid expenses and other 2,005 284
-------------------------------------------------------------------------
31,612 22,978
CAPITAL ASSETS, net 535 646
INTANGIBLE ASSET, net 323 375
LONG-TERM INVESTMENT 264 264
-------------------------------------------------------------------------
$ 32,734 $ 24,263
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES
CURRENT
Accounts payable and accrued liabilities $ 2,801 $ 2,801
Current portion of capital lease obligation 45 45
Current portion of deferred revenue 207 207
-------------------------------------------------------------------------
3,053 3,053
CAPITAL LEASE OBLIGATION 57 81
DEFERRED REVENUE 932 1,036
CLASS A PREFERENCE SHARES 30 30
-------------------------------------------------------------------------
4,072 4,200
-------------------------------------------------------------------------
SHAREHOLDERS' EQUITY
Share capital (Notes 3 and 4) 389,447 375,497
Issued and outstanding - 89,388,932
and 78,816,564
Warrants (Note 3) 6,483 2,959
Contributed surplus (Note 4) 20,713 19,779
Deficit (387,981) (378,172)
-------------------------------------------------------------------------
28,662 20,063
-------------------------------------------------------------------------
$ 32,734 $ 24,263
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(see accompanying notes to the consolidated financial statements)
(CAD $1.00 (equal sign) USD $0.90)
(x) Figures excerpted from the 2005 audited consolidated financial
statements.
Biomira Inc.
Consolidated Statements of Operations
(expressed in thousands of Canadian dollars, except share and per share
amounts)
(unaudited)
Three Months Ended Six Months Ended
June 30 June 30
2006 2005 2006 2005
-------------------------------------------------------------------------
REVENUE
Contract research
and development $ 1,020 $ 1,068 $ 1,344 $ 1,659
Licensing revenue
from collaborative
agreements 51 52 106 104
Licensing,
royalties, and
other revenue 85 - 86 161
-------------------------------------------------------------------------
1,156 1,120 1,536 1,924
-------------------------------------------------------------------------
EXPENSES
Research and
development 2,972 4,320 6,928 7,827
General and
administrative 2,134 1,562 4,264 3,285
Marketing and
business
development 149 389 367 657
Amortization 97 84 203 168
-------------------------------------------------------------------------
5,352 6,355 11,762 11,937
-------------------------------------------------------------------------
OPERATING LOSS (4,196) (5,235) (10,226) (10,013)
Investment and
other income 187 432 424 852
Interest expense - - (7) -
-------------------------------------------------------------------------
NET LOSS $ (4,009) $ (4,803) $ (9,809) $ (9,161)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
BASIC AND DILUTED
LOSS PER SHARE $ (0.04) $ (0.06) $ (0.11) $ (0.12)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
WEIGHTED AVERAGE
NUMBER OF COMMON
SHARES
OUTSTANDING 89,388,932 78,499,836 87,636,606 78,499,836
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(See accompanying notes to the consolidated financial statements)
Consolidated Statements of Deficit
(expressed in thousands of Canadian dollars)
(unaudited)
Three Months Ended Six Months Ended
June 30 June 30
2006 2005 2006 2005
-------------------------------------------------------------------------
DEFICIT, BEGINNING
OF PERIOD $ (383,972) $ (363,505) $ (378,172) $ (359,147)
Net loss for period (4,009) (4,803) (9,809) (9,161)
-------------------------------------------------------------------------
DEFICIT, END OF
PERIOD $ (387,981) $ (368,308) $ (387,981) $ (368,308)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(See accompanying notes to the consolidated financial statements)
Biomira Inc.
Consolidated Statements of Cash Flow
(expressed in thousands of Canadian dollars)
(unaudited)
Three Months Ended Six Months Ended
June 30 June 30
2006 2005 2006 2005
-------------------------------------------------------------------------
OPERATING
Net loss $ (4,009) $ (4,803) $ (9,809) $ (9,161)
Amortization 97 84 203 168
Stock compensation
expense (Note 4) 390 297 934 487
Decrease in deferred
revenue (52) (156) (104) (324)
Unrealized foreign
exchange loss (gain)
on cash and cash
equivalents 97 34 54 (20)
Net change in non-cash
working capital
balances from
operations
Accounts receivable (331) (503) 409 (379)
Prepaid expenses
and other (769) (149) (1,721) (144)
Accounts payable and
accrued liabilities (285) 335 - 53
-------------------------------------------------------------------------
(4,862) (4,861) (10,034) (9,320)
-------------------------------------------------------------------------
INVESTING
Purchase of short-term
investments (12,759) (19,302) (29,933) (34,280)
Redemption of short-term
investments 13,235 10,991 24,810 26,597
Purchase of capital
assets (40) (95) (40) (135)
-------------------------------------------------------------------------
436 (8,406) (5,163) (7,818)
-------------------------------------------------------------------------
FINANCING
Proceeds on issue of
common shares and
warrants, net of issue
costs (25) - 17,474 (100)
Proceeds from exercise
of stock options 3 - 45
Proceeds from exercise
of warrants 950 - 950
Repayment of capital
lease obligation (12) - (24) -
-------------------------------------------------------------------------
(37) 953 17,450 895
-------------------------------------------------------------------------
NET CASH (OUTFLOW)
INFLOW (4,463) (12,314) 2,253 (16,243)
EFFECT OF EXCHANGE RATE
FLUCTUATIONS ON CASH AND
CASH EQUIVALENTS (97) (34) (54) 20
-------------------------------------------------------------------------
(DECREASE) INCREASE IN CASH
AND CASH EQUIVALENTS (4,560) (12,348) 2,199 (16,223)
CASH AND CASH EQUIVALENTS,
BEGINNING OF PERIOD 16,023 16,012 9,264 19,887
-------------------------------------------------------------------------
CASH AND CASH EQUIVALENTS,
END OF PERIOD $ 11,463 $ 3,664 $ 11,463 $ 3,644
-------------------------------------------------------------------------
-------------------------------------------------------------------------
SUPPLEMENTAL DISCLOSURE
OF CASH FLOW
INFORMATION
Amount of interest
paid in the period $ - $ - $ 7 $ -
Amount of income taxes
paid in the period $ - $ - $ - $ -
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(See accompanying notes to the consolidated financial statements)
BIOMIRA INC.
Notes to the Consolidated Financial Statements
(expressed in thousands of Canadian dollars, except share and per share
amounts)
(unaudited)
-------------------------------------------------------------------------
1. BASIS OF PRESENTATION
The accompanying unaudited consolidated interim financial statements
have been prepared by the Company in accordance with Canadian
generally accepted accounting principles (Canadian GAAP) for interim
financial statements. The accounting principles and methods of
computation adopted in these consolidated financial statements are
the same as those of the audited consolidated financial statements
for the year ended December 31, 2005, except as disclosed in Note 2
below.
Omitted from these statements are certain information and note
disclosures normally included in the annual consolidated financial
statements prepared in accordance with Canadian GAAP. The
consolidated financial statements and notes presented should be read
in conjunction with the audited consolidated financial statements for
the year ended December 31, 2005 filed with the appropriate
securities commissions.
2. ACCOUNTING POLICY CHANGES
Non-monetary transactions
Effective January 1, 2006, the Company adopted the recommendations of
CICA Handbook Section 3831, Non-Monetary Transactions, replacing
Section 3830 of the same title. The new accounting standard requires
all non-monetary transactions be measured at fair value unless
certain conditions are satisfied. The new requirements are effective
for non-monetary transactions initiated in periods beginning on or
after January 1, 2006.
The Company has determined that adoption of Section 3831 does not
have an effect on our financial position or results of operations in
the current period presented.
Implicit variable interests under AcG-15
Effective January 1, 2006, the Company adopted the recommendations of
Abstract No. 157, Implicit Variable Interests under AcG-15 (EIC-157).
The new abstract addresses whether a company has an implicit variable
interest in a variable interest entity (VIE) or potential VIE when
specific conditions exist. An implicit variable interest acts the
same as an explicit variable interest except it involves the
absorbing and/or receiving of variability indirectly from the entity
(rather than directly). The identification of an implicit variable
interest is a matter of judgment that depends on the relevant facts
and circumstances.
The Company has determined that adoption of EIC-157 does not have an
effect on our financial position, results of operations or cash flows
in the current period presented.
3. SHARE CAPITAL
June 30 December 31
2006 2005
---------------------------------------------------------------------
Common shares
Issued and outstanding, beginning of
period 78,816,564 78,339,978
Equity placements 10,572,368 -
Exercise of warrants - 454,679
Exercise of stock options - 21,907
---------------------------------------------------------------------
Issued and outstanding, end of period 89,388,932 78,816,564
---------------------------------------------------------------------
---------------------------------------------------------------------
Issued and outstanding as at July 14, 2006 89,388,932
---------------------------------------------------------------------
---------------------------------------------------------------------
June 30 December 31
2006 2005
---------------------------------------------------------------------
Warrants
Issued and outstanding, beginning of
period 1,077,121 3,631,800
Issued 2,748,816 -
Exercised - (454,679)
Expired - (2,100,000)
---------------------------------------------------------------------
Issued and outstanding, end of period 3,825,937 1,077,121
---------------------------------------------------------------------
---------------------------------------------------------------------
Issued and outstanding as at July 14, 2006 3,825,937
---------------------------------------------------------------------
---------------------------------------------------------------------
The warrants provide the holders with the right to purchase common
shares at a range of prices from U.S. $2.50 to U.S. $3.45 per share.
In January 2006, the Company issued 10,572,368 common shares and
2,748,816 detachable warrants for proceeds of $18,389, before issue
costs of $915. Of the net proceeds, $13,950 and $3,524 have been
allocated to common shares and warrants, respectively. The warrants
have an exercise price of U.S. $2.50 and are not exercisable until
after July 30, 2006, with the exception of 105,724 warrants that are
not exercisable until after January 30, 2007. The 2,748,816 warrants
expire on July 30, 2009.
The Company used the Black-Scholes option pricing model to calculate
the fair value of the warrants issued.
June 30 December 31
2006 2005
---------------------------------------------------------------------
Stock options
Outstanding, beginning of period 4,360,940 3,736,599
Granted 48,500 1,282,065
Exercised - (21,907)
Cancelled (353,793) (635,817)
---------------------------------------------------------------------
Outstanding, end of period 4,055,647 4,360,940
---------------------------------------------------------------------
---------------------------------------------------------------------
Outstanding as at July 14, 2006 4,055,647
---------------------------------------------------------------------
---------------------------------------------------------------------
Stock options are exercisable at a range of exercise prices from
$1.30 to $23.10 per share.
June 30 December 31
2006 2005
---------------------------------------------------------------------
Restricted Share Units
Outstanding, beginning of period 114,000 -
Granted - 114,000
---------------------------------------------------------------------
Outstanding, end of period 114,000 114,000
---------------------------------------------------------------------
---------------------------------------------------------------------
Outstanding as at July 14, 2006 114,000
---------------------------------------------------------------------
---------------------------------------------------------------------
Each restricted share unit will be converted into one common share at
the end of the grant period (not to exceed five years) without any
further consideration payable.
4. STOCK-BASED COMPENSATION
Stock Option Plan
In the second quarter of 2006, stock compensation expense of $381
(2005 - $297) was recognized ($915 for the six months ended June 30,
2006 (2005 - $487)), representing the amortization applicable to the
current period of the estimated fair value of stock options granted
since January 1, 2002. The expense for the six months ended June 30,
2006 includes an adjustment of $244 relating to workforce reduction
costs described in Note 6. This adjustment includes the immediate
expensing of the remaining unamortized fair value of the affected
stock options and a modification adjustment relating to extension of
the expiry date of the affected stock options to 24 months from the 6
months provided in the original stock option agreements.
An amount of nil (2005 - $31) arising from the exercise of stock
options for the six months ended June 30, 2006 was credited to share
capital from contributed surplus.
The Company uses the Black-Scholes option pricing model to value the
stock options at each grant date, under the following weighted
average assumptions:
Six Months Ended June 30
2006 2005
---------------------------------------------------------------------
Weighted average grant-date fair value per
share option $ 1.35 $ 2.24
Expected dividend rate 0.0% 0.0%
Expected volatility 106.63% 114.26%
Risk-free interest rate 4.19% 3.69%
Expected life of options in years 6.0 6.0
---------------------------------------------------------------------
---------------------------------------------------------------------
The amounts estimated according to the Black-Scholes option pricing
model may not be indicative of the actual values realized upon the
exercise of these stock options by the holders.
Restricted Share Unit Plan
In the second quarter of 2006, stock compensation expense of $9
(2005 - nil) was recognized ($19 for the six months ended June 30,
2006 (2005 - nil)), representing the amortization applicable to the
current period of the estimated fair value of restricted share units
granted.
5. COLLABORATIVE AGREEMENTS
On January 26, 2006, Biomira announced the signing of a letter of
intent to amend the existing supply and collaboration agreements
between Biomira and Merck KGaA of Darmstadt, Germany (Merck) for
Stimuvax(R), currently in development for the treatment of non-small
cell lung cancer (NSCLC).
Under the letter of intent, approved by the Boards of both Companies,
effective March 1, 2006 Merck will assume most of the administrative
and financial responsibility for the development and
commercialization of Stimuvax(R), including the planned phase 3 trial
in NSCLC, which is expected to commence by the end of the year. Merck
also plans to investigate the use of Stimuvax(R) to treat other types
of cancer.
In return, under the letter of intent, Biomira's co-promotion
interest in U.S. sales will be converted to a specified royalty rate,
which will be higher than what Merck has agreed to pay on its sales
of Stimuvax(R) in markets outside of North America (the Rest of World
(ROW)). The royalty and other arrangements with respect to the ROW
will remain generally unchanged (Merck to assume a specified third
party royalty obligation on behalf of Biomira). Similarly, the
milestone payments to be made by Merck pursuant to the collaboration
will remain essentially the same. The agreed upon royalty rate for
the U.S. territory reflects the current stage and promise of
Stimuvax(R).
Under the letter of intent, Biomira will retain responsibility for
manufacturing Stimuvax(R), both for clinical trials and following any
marketing approval. The existing arrangements for Canada remain in
place with Biomira responsible for the Canadian territory.
The Companies are currently in the process of revising the existing
supply and collaboration agreements to reflect the terms contained
within the letter of intent.
6. WORKFORCE REDUCTION COSTS
As a result of the signing of the letter of intent described in
Note 5, Biomira has initially reduced its workforce by 16 employees.
In total, the Company recorded workforce reduction costs of $1,436
for the six months ended June 30, 2006, of which $1,233 and $203 have
been reported as research and development and general and
administrative respectively in the consolidated statement of
operations.
Once the transfer of the Stimuvax(R) phase 3 clinical trial
activities to Merck has been completed, the Company will engage in a
limited reorganization to reflect the reduced activities previously
associated with Stimuvax(R).
The following table provides details of the workforce reduction costs
for the six months ended June 30, 2006:
Cumulative
Workforce Drawdowns Accrued Workforce
Reduction -------------- Reduction Costs at
Costs Cash Non-Cash June 30, 2006
---------------------------------------------------------------------
Salaries and benefits $ 1,150 $ 816 $ - $ 334
Stock compensation
expense (Note 4) 244 - 244 -
Other 42 38 - 4
---------------------------------------------------------------------
$ 1,436 $ 854 $ 244 $ 338
---------------------------------------------------------------------
---------------------------------------------------------------------
7. SEGMENTED INFORMATION
The Company is engaged worldwide primarily in the biotechnology
healthcare industry in a single business segment, research and
development of therapeutic products for the treatment of cancer.
Operations and long-lived assets by geographic region for the periods
indicated are as follows:
Three Months Ended Six Months Ended
June 30 June 30
2006 2005 2006 2005
---------------------------------------------------------------------
Revenue from operations in
Canada $ 133 $ 57 $ 156 $ 248
United States - - - 1
Barbados 1,004 1,044 1,341 1,636
Europe 19 19 39 39
---------------------------------------------------------------------
$ 1,156 $ 1,120 $ 1,536 $ 1,924
---------------------------------------------------------------------
---------------------------------------------------------------------
Three Months Ended Six Months Ended
June 30 June 30
2006 2005 2006 2005
---------------------------------------------------------------------
Amortization in
Canada $ 62 $ 51 $ 132 $ 103
United States 9 7 19 13
Barbados 26 26 52 52
---------------------------------------------------------------------
$ 97 $ 84 $ 203 $ 168
---------------------------------------------------------------------
June 30 December 31
2006 2005
---------------------------------------------------------------------
Long-lived assets, net, in
Canada $ 501 $ 593
United States 34 53
Barbados 323 375
---------------------------------------------------------------------
$ 858 $ 1,021
---------------------------------------------------------------------
---------------------------------------------------------------------
Long-lived assets and amortization consist of capital assets and
intangible assets and the amortization of capital assets and
intangible assets recorded thereon.
The Company derives significant revenue from certain customers. The
number of customers that individually accounts for more than 10% of
revenue and total revenue from transactions with those customers are
as follows:
Six Months Ended June 30 Number of Customers Revenue
---------------------------------------------------------------------
2006 1 $ 1,439
2005 1 $ 1,754
>>
Corporate Information
Share Registrar and Transfer Agents
Computershare Investor Services Inc.
Suite 600, 530 - 8 Ave SW
Calgary AB T2P 3S8
Canada
Phone: 1-800-564-6253 (toll free North America)
Phone: 1-514-982-7555 (International)
Fax: 1-888-453-0330 (toll free North America)
Fax: 1-416-263-9394 (International)
E-Mail: service(at)computershare.com
Internet: http://www.computershare.com
Stock Listings and Symbols
Toronto Stock Exchange: BRA
Nasdaq Global Market: BIOM
We invite you to visit our web site at www.biomira.com or call our
investor relations department toll free at 1-877-234-0444 Ext. 241.
This release/report may contain forward-looking statements. Various
factors could cause actual results to differ materially from those
projected in such statements, a number of which are set forth under the
Management Discussion and Analysis section above. All forward-looking
statements in this release/report are expressly qualified in their
entirety by this cautionary statement and by the section on Forward-
Looking Statements under the Management Discussion and Analysis section.
